<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890422</url>
  </required_header>
  <id_info>
    <org_study_id>ASOKLIF 0608/MI</org_study_id>
    <secondary_id>Eudract number: 2006-006955-10</secondary_id>
    <nct_id>NCT00890422</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine</brief_title>
  <acronym>immunisation</acronym>
  <official_title>Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elisabethinen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASOKLIF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elisabethinen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to answer this question: whether adequate immunity can be achieved in a short
      time, that is, by a rapid immunisation process, using at least one of 3 new TBE immunisation
      schedules? The investigators will test the immunogenicity (the degree of immunity achieved)
      of each of the immunisation schedules at various times after the injections. If the results
      of this clinical study are positive, it may then be possible to develop the most successful
      immunisation schedule so that it can be used routinely. This means that the results of the
      clinical study have an enormous practical value in preventing TBE in people travelling or
      moving into areas with a high TBE risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data from at least 99 individuals will be needed if the study is to draw reliable
      conclusions. One-third of these individuals will receive 3 injections in all: 2 on the first
      day and the third injection 4 days later (immunisation schedule 1). Another one-third will
      receive 2 injections in all: one on the first day and one injection 4 days later
      (immunisation schedule 2). The remaining one-third will also receive 2 injections, both of
      these on the first day (immunisation schedule 3). Participants will be assigned completely
      randomly (by chance) to one of these three groups. So each participant stands a 33% chance (a
      1:2 chance) of receiving any one particular immunisation schedule. If you agree to take part,
      the process will be as follows:

      Brief Overview of the Course of the Clinical Study:

      Vaccination scheme 1

      Vaccination scheme 2

      Vaccination scheme 3

      Vaccinations:

      I = Vaccination with FSME-IMMUN 0,5ml

        -  Scheme 1: 2 vaccinations at U1 (day 0), one injection into the left and the right upper
           arm each, 1 vaccination at U2 (day 4), injection into the left upper arm

        -  Scheme 2: one vaccination at U1 (day 0) and at U2 (day 4), injections into the left
           upper arm each

        -  Scheme 3: 2 vaccinations at U1 (day 0), one injection into the left and the right upper
           arm each
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>achievement of FSME-Antibody-level (IgG) &gt;25IU/ml at visit U2, U3, U4, U5, U6, U7, U8 and U9-yes/no achievement of FSME antibody-level (IgG) of &gt;126VIEU/ml at U2, U3;U4, U5, U6, U7, U8 and U9-yes/no</measure>
    <time_frame>U2 (=day4) U3 (=day7) U4 (=day10) U5 (=day 14) U6 (=day21) U7 (=day28) U8 (=day42) U9 (=day56)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FSME antibody level at U2, U3, U4, U5, U6, U7, U8 and U9</measure>
    <time_frame>U2 (=day4) U3 (=day7) U4 (=day10) U5 (=day 14) U6 (=day21) U7 (=day28) U8 (=day42) U9 (=day56)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Tick Borne Encephalitis</condition>
  <arm_group>
    <arm_group_label>1FSME vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vaccination on day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 FSME vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 vaccination on day 0 and one vaccination on day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 FSME vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vaccinations on day 0 and 1 vaccination on day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FSME vaccination (FSME-Immun)</intervention_name>
    <description>intra muscular 0.5 ml</description>
    <arm_group_label>1FSME vaccination</arm_group_label>
    <arm_group_label>2 FSME vaccination</arm_group_label>
    <arm_group_label>3 FSME vaccination</arm_group_label>
    <other_name>FSME-Immun 0.5 ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  FSME antibody level &lt; 7IU/ml (ELISA), retrospective

          -  FSME antibody (IgG) &lt; 63 VIEU/ml (ELISA), retrospective

          -  FSME antibody (IgM) negative

          -  FSME antibody inhibition capacity &lt;1:10-retrospective

          -  available for the next 56 days

        Exclusion Criteria:

          -  age not 19 or over 65

          -  pregnancy

          -  risk of becoming pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut Mittermayer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elisabethinen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elisabethinen Hospital</name>
      <address>
        <city>Linz</city>
        <state>upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>nemocnice ceske Budejovice</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>37087</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>http://www.elisabethinen.or.at</url>
    <description>ethics committee of the Elisabethinen hospital</description>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Helmut Mittermayer/Univ.Prof. Dr.</name_title>
    <organization>Elisabethinen Hospital</organization>
  </responsible_party>
  <keyword>encephalitis</keyword>
  <keyword>FSME</keyword>
  <keyword>central european encephalitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

